INF2 and polyarteritis nodosa: Thus, we tested the protective effects of bortezomib in our established model, INF2 R218Q KI mice with PAN, which is a representative in vivo model of human R218Q-mediated FSGS.4 In R218Q KI mice treated with PA, we hypothesize that the PA interacts with a defect in the podocyte caused by the R218Q mutation, resulting in a more prominent effect than PA with wild-type mice.